Department of Thoracic Surgery, Glenfield Hospital, University Hospitals of Leicester, Leicester, UK.
Eur J Cardiothorac Surg. 2017 Nov 1;52(5):982-988. doi: 10.1093/ejcts/ezx242.
Lung volume reduction surgery (LVRS) has been demonstrated to provide symptomatic relief and improve lung function in patients with end-stage emphysema. The National Emphysema Treatment Trial specifically noted functional benefits in patients with predominantly upper lobe emphysema and demonstrated improvement in quality-of-life parameters, in patients with non-upper lobe emphysema and a low-baseline exercise capacity. We aimed to investigate whether physiological and health status benefits correlated with lower lobe LVRS.
A retrospective analysis was performed from our prospectively collected patient database. A total of 36 patients with severe, non-upper lobe predominant emphysema underwent lower lobe LVRS in our institution, over a 20-year period. The assessments consisted of measurements of body mass index, pulmonary function tests and health-related quality of life using the Short Form 36-item questionnaires.
Forced expiratory volume in 1 s was seen to improve 3 months [coefficient of time = 1.55 (0.88, 2.21); P < 0.0001] after the procedure, maintained until the first 6 months [0.48 (0.12, 0.85); P = 0.010], decline over the second half of the first year and gradually return to preoperative levels after 2 years, while residual volume to total lung capacity (%) ratio was seen to follow a similar pattern with significant decrease from baseline after 3 months [coefficient of time = -1.76 (-2.75, -0.76); P = 0.001] and 6 months [-1.05 (-1.51, -0.59); P < 0.0001]. Quality-of-life improvements were mainly noted in physical components.
Contrary to a widely held misconception following the National Emphysema Treatment Trial that lower lobe lung volume reduction does not offer significant benefits to patients with non-upper lobe predominant emphysema, we feel justified in offering lower lobe LVRS in these patients when they meet the same selection criteria as upper lobe LVRS.
肺减容术(LVRS)已被证实可缓解终末期肺气肿患者的症状并改善肺功能。国家肺气肿治疗试验(National Emphysema Treatment Trial)特别指出,主要在上肺叶肺气肿患者中具有功能益处,并在非上肺叶肺气肿和低基线运动能力的患者中改善了生活质量参数。我们旨在研究生理和健康状况的改善是否与下叶 LVRS 相关。
我们对前瞻性收集的患者数据库进行了回顾性分析。在我们的机构中,20 年来共有 36 例严重的非上肺叶为主的肺气肿患者接受了下叶 LVRS。评估包括身体质量指数(BMI)、肺功能测试和使用短格式 36 项问卷进行的健康相关生活质量的测量。
术后 3 个月时,1 秒用力呼气量(FEV1)改善[时间系数=1.55(0.88,2.21);P<0.0001],直至术后 6 个月[0.48(0.12,0.85);P=0.010],在第一年的下半年下降,然后在术后 2 年内逐渐恢复到术前水平,而残气量/肺总量(RV/TLC)比值也呈现出类似的模式,术后 3 个月时从基线显著下降[时间系数=-1.76(-2.75,-0.76);P=0.001]和术后 6 个月时下降[-1.05(-1.51,-0.59);P<0.0001]。生活质量的改善主要体现在身体成分方面。
与国家肺气肿治疗试验(National Emphysema Treatment Trial)后普遍存在的误解相反,即下叶肺减容术对非上肺叶为主的肺气肿患者没有显著益处,我们认为,当这些患者符合与上叶 LVRS 相同的选择标准时,应在下叶进行 LVRS。